Expansion of contracted preclinical testing services for nucleic acid pharmaceuticals through a comprehensive business alliance with Bonac
First written in FY2020-Q1. 4 of 8 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「In October 2025, we entered into a business partnership with 北海道システム・サイエンス株式会社 to establish a framework capable of providing integrated support for nucleic acid drug development, from synthesis through clinical trials, among other objectives.」
For nucleic acid drugs, the company has reconfirmed the alliance under which the scope of initiatives expanded from expanding outsourced nonclinical studies to establishing a framework for integrated support from synthesis through clinical trials. - FY2026-H1RaisedAnnual report
「In October 2025, the company entered into a business alliance with 北海道システム・サイエンス株式会社 to establish a framework capable of providing integrated support for nucleic acid drug development from synthesis through clinical trials, and pursued activities aimed at sustainable growth going forward.」
For nucleic acid drugs, the scope of the company’s initiatives expanded beyond the previous expansion of outsourced nonclinical studies to a business alliance aimed at establishing a framework for integrated support from synthesis through clinical trials. - FY2020RestatedAnnual report
「The company entered into a comprehensive business alliance with ボナック株式会社 to expand outsourced nonclinical studies, providing access to the group’s research facilities, laboratory equipment and researchers for the expansion and commercialization of the nucleic acid drug pipeline being developed by ボナック株式会社.」
The comprehensive business alliance to provide facilities, equipment and personnel for the expansion and commercialization of ボナック’s nucleic acid drug pipeline is continuing. - FY2020-Q3RestatedAnnual report
「The company also entered into a comprehensive business alliance with ボナック株式会社 to expand outsourced nonclinical studies, providing access to the group’s research facilities, laboratory equipment and researchers for the expansion and commercialization of the nucleic acid drug pipeline being developed by ボナック株式会社.」
The company has reconfirmed its comprehensive business alliance to use the group’s facilities, equipment and personnel to expand and commercialize ボナック’s nucleic acid drug pipeline. - FY2020-Q2RestatedAnnual report
「The company also entered into a comprehensive business alliance with ボナック株式会社 to expand outsourced nonclinical studies, providing access to the group’s research facilities, laboratory equipment and researchers for the expansion and commercialization of the nucleic acid drug pipeline being developed by ボナック株式会社.」
The company has reconfirmed its comprehensive business alliance to use the group’s facilities, equipment and personnel to expand and commercialize ボナック’s nucleic acid drug pipeline. - FY2020-Q1First statedAnnual report
「The company also entered into a comprehensive business alliance with ボナック株式会社 to expand outsourced nonclinical studies, providing access to the group’s research facilities, laboratory equipment and researchers for the expansion and commercialization of the nucleic acid drug pipeline being developed by ボナック株式会社. CRO business orders for the first 3 quarters of the current fiscal year increased to ¥529.215 million, up 7.6% year on year.」
A new comprehensive business alliance was concluded to use the group’s facilities, equipment and personnel to expand and commercialize ボナック’s nucleic acid drug pipeline. CRO business orders totaled ¥529.215 million, up 7.6% year on year.